$25.85
0.20.78%
At Close: -
$26.38
0.532.03%
After Hours: Jul 3, 4:15 PM EDT
15 minutes delayed
Artivion
AORTNYSE
Artivion (NYSE:AORT) Stock, Insider Trading Activity
Artivion: Insider buying and selling updated today.
Institutional Shares Held
22.683M
Institutional Percentage Held
54.4%
| May 13, 2024 | Jean F Holloway | SVP, GENERAL COUNSEL | -1.25K | $23.42 | -$29.28K | SELL | -0.74% | 167.482K | May 10 | View |
| May 10, 2024 | Jean F Holloway | SVP, GENERAL COUNSEL | -979 | $23.79 | -$23.29K | SELL | -0.58% | 168.732K | May 09 | View |
| Mar 21, 2024 | Marshall Stanton | SVP, CLINICAL & MD AFFAIR | -2.183K | $20.39 | -$44.51K | SELL | -2.55% | 83.296K | Mar 20 | View |
| Mar 18, 2024 | Andrew M Green | VP REGULATORY | -1.462K | $20.00 | -$29.24K | SELL | -3.43% | 41.121K | Mar 15 | View |
| Mar 15, 2024 | Andrew M Green | VP REGULATORY | -3.994K | $20.00 | -$79.88K | SELL | -8.58% | 42.583K | Mar 14 | View |
| Mar 14, 2024 | Matthew A Getz | VP, HUMAN RESOURCES | -5K | $19.94 | -$99.72K | SELL | -10.30% | 43.536K | Mar 12 | View |
| Mar 07, 2024 | James P Mackin | PRESIDENT & CEO | 14.622K | $18.72 | -$262.04K | GRANT | 2.12% | 705.562K | Mar 01 - Mar 05 | View |
| Mar 07, 2024 | Jean F Holloway | SVP, GENERAL COUNSEL | 3.344K | $18.72 | -$44.56K | GRANT | 2.01% | 169.669K | Mar 01 - Mar 05 | View |
| Mar 07, 2024 | John E Davis | CHIEF COMMERCIAL OFFICER | 3.702K | $18.72 | -$37.86K | GRANT | 2.29% | 165.637K | Mar 01 - Mar 05 | View |
| Mar 07, 2024 | Matthew A Getz | VP, HUMAN RESOURCES | 2.421K | $18.72 | -$21.66K | GRANT | 5.25% | 48.503K | Mar 01 - Mar 05 | View |
| Mar 07, 2024 | Rochelle Maney | VP, QUALITY | 2.421K | $18.72 | -$21.66K | GRANT | 5.49% | 46.536K | Mar 01 - Mar 05 | View |
| Mar 07, 2024 | Andrew M Green | VP REGULATORY | 2.418K | $18.72 | -$21.72K | GRANT | 5.48% | 46.541K | Mar 01 - Mar 05 | View |
| Mar 07, 2024 | Marshall Stanton | SVP, CLINICAL & MD AFFAIR | 4.218K | $18.72 | -$28.20K | GRANT | 5.19% | 85.438K | Mar 01 - Mar 05 | View |
| Mar 07, 2024 | Amy Horton | VP, CHIEF ACCOUNTING OFFICER | 2.426K | $18.72 | -$21.57K | GRANT | 1.76% | 139.957K | Mar 01 - Mar 05 | View |
| Feb 29, 2024 | Florian Tyrs | VP, GLOBAL OPERATIONS | -339 | $19.83 | -$6.72K | SELL | -1.30% | 25.689K | Feb 27 | View |
| Feb 29, 2024 | Amy Horton | VP, CHIEF ACCOUNTING OFFICER | -325 | $19.83 | -$6.45K | SELL | -0.24% | 137.531K | Feb 27 | View |
| Feb 29, 2024 | James P Mackin | PRESIDENT & CEO | -4.837K | $19.83 | -$95.94K | SELL | -0.70% | 690.94K | Feb 27 | View |
| Feb 29, 2024 | Jean F Holloway | SVP, GENERAL COUNSEL | -485 | $19.83 | -$9.62K | SELL | -0.29% | 166.325K | Feb 27 | View |
| Feb 29, 2024 | John E Davis | CHIEF COMMERCIAL OFFICER | -584 | $19.83 | -$11.58K | SELL | -0.36% | 161.935K | Feb 27 | View |
| Feb 29, 2024 | Rochelle Maney | VP, QUALITY | -370 | $19.83 | -$7.34K | SELL | -0.83% | 44.115K | Feb 27 | View |
| Feb 29, 2024 | Matthew A Getz | VP, HUMAN RESOURCES | -325 | $19.83 | -$6.45K | SELL | -0.70% | 46.082K | Feb 27 | View |
| Feb 29, 2024 | Andrew M Green | VP REGULATORY | -421 | $19.83 | -$8.35K | SELL | -0.95% | 44.123K | Feb 27 | View |
| Feb 29, 2024 | Marshall Stanton | SVP, CLINICAL & MD AFFAIR | -465 | $19.83 | -$9.22K | SELL | -0.57% | 81.22K | Feb 27 | View |
| Feb 28, 2024 | Amy Horton | VP, CHIEF ACCOUNTING OFFICER | 7.618K | $20.27 | -$43.91K | GRANT | 5.85% | 137.856K | Feb 23 - Feb 26 | View |
| Feb 28, 2024 | James P Mackin | PRESIDENT & CEO | 67.74K | $20.27 | -$634.73K | GRANT | 10.79% | 695.777K | Feb 23 - Feb 26 | View |
| Feb 28, 2024 | Jean F Holloway | SVP, GENERAL COUNSEL | 15.342K | $20.27 | -$58.38K | GRANT | 10.13% | 166.81K | Feb 23 - Feb 26 | View |
| Feb 28, 2024 | Rochelle Maney | VP, QUALITY | 7.469K | $20.27 | -$46.93K | GRANT | 20.18% | 44.485K | Feb 23 - Feb 26 | View |
| Feb 28, 2024 | John E Davis | CHIEF COMMERCIAL OFFICER | 14.608K | $20.27 | -$71.23K | GRANT | 9.88% | 162.519K | Feb 23 - Feb 26 | View |
| Feb 28, 2024 | Matthew A Getz | VP, HUMAN RESOURCES | 8.465K | $20.27 | -$46.89K | GRANT | 22.31% | 46.407K | Feb 23 - Feb 26 | View |
| Feb 28, 2024 | Andrew M Green | VP REGULATORY | 7.877K | $20.27 | -$48.71K | GRANT | 21.48% | 44.544K | Feb 23 - Feb 26 | View |
| Feb 28, 2024 | Marshall Stanton | SVP, CLINICAL & MD AFFAIR | 12.982K | $20.27 | -$61.79K | GRANT | 18.90% | 81.685K | Feb 23 - Feb 26 | View |
| Feb 28, 2024 | Florian Tyrs | VP, GLOBAL OPERATIONS | -893 | $20.27 | -$18.10K | SELL | -3.31% | 26.065K | Feb 26 | View |
| Feb 22, 2024 | Jean F Holloway | SVP, GENERAL COUNSEL | -3.527K | $18.86 | -$66.54K | SELL | -2.61% | 131.858K | Feb 20 | View |
| Feb 22, 2024 | Amy Horton | VP, CHIEF ACCOUNTING OFFICER | -1.695K | $18.86 | -$31.98K | SELL | -1.37% | 122.345K | Feb 20 | View |
| Feb 22, 2024 | John E Davis | CHIEF COMMERCIAL OFFICER | -2.556K | $18.86 | -$48.22K | SELL | -1.96% | 128.177K | Feb 20 | View |
| Feb 22, 2024 | Rochelle Maney | VP, QUALITY | -407 | $18.86 | -$7.68K | SELL | -1.38% | 29.123K | Feb 20 | View |
| Feb 22, 2024 | Matthew A Getz | VP, HUMAN RESOURCES | -1.695K | $18.86 | -$31.98K | SELL | -5.58% | 28.692K | Feb 20 | View |
| Feb 22, 2024 | Florian Tyrs | VP, GLOBAL OPERATIONS | -249 | $18.86 | -$4.70K | SELL | -1.28% | 19.174K | Feb 20 | View |
| Feb 22, 2024 | James P Mackin | PRESIDENT & CEO | -12.844K | $17.58 | -$393.45K | SELL | -2.33% | 539.036K | Feb 20 | View |
| Jan 04, 2024 | Jean F Holloway | SVP, GENERAL COUNSEL | 0 | $17.15 | -$36.09K | SELL-OPTIONS | 0.00% | 133.52K | Jan 02 | View |
| Jan 04, 2024 | John E Davis | SENIOR VP, GLOBAL SALES | 0 | $17.15 | -$23.06K | SELL-OPTIONS | 0.00% | 128.733K | Jan 02 | View |
| Dec 19, 2023 | Amy Horton | VP, CHIEF ACCOUNTING OFFICER | 0 | $17.65 | -$38.87K | SELL-OPTIONS | 0.00% | 124.04K | Dec 15 | View |
| Nov 29, 2023 | Amy Horton | VP, CHIEF ACCOUNTING OFFICER | -3.851K | $17.42 | -$67.07K | SELL | -3.58% | 103.849K | Nov 27 | View |
| Jun 08, 2023 | Dennis Maier | SVP, OPERATIONS | -16.254K | $15.27 | -$248.16K | SELL | -31.88% | 34.724K | Jun 06 | View |
| Jun 08, 2023 | Matthew A Getz | VP, HUMAN RESOURCES | -6.329K | $15.88 | -$100.48K | SELL | -17.24% | 30.387K | Jun 07 | View |
| Mar 03, 2023 | Dennis Maier | SVP, OPERATIONS | 2.542K | $13.41 | -$15.03K | GRANT | 5.25% | 50.978K | Mar 01 - Mar 02 | View |
| Mar 03, 2023 | Rochelle Maney | VP, QUALITY | 1.469K | $13.41 | -$11.01K | GRANT | 5.24% | 29.53K | Mar 01 - Mar 02 | View |
| Mar 03, 2023 | Amy Horton | VP, CHIEF ACCOUNTING OFFICER | 1.588K | $13.41 | -$9.42K | GRANT | 1.50% | 107.7K | Mar 01 - Mar 02 | View |
| Mar 03, 2023 | Matthew A Getz | VP, HUMAN RESOURCES | 1.588K | $13.41 | -$9.42K | GRANT | 4.52% | 36.716K | Mar 01 - Mar 02 | View |
| Mar 03, 2023 | James P Mackin | PRESIDENT & CEO | 11.828K | $13.41 | -$133.98K | GRANT | 2.19% | 551.88K | Mar 01 - Mar 02 | View |
| Mar 03, 2023 | Andrew M Green | VP REGULATORY | 1.465K | $13.41 | -$11.06K | GRANT | 6.08% | 25.567K | Mar 01 - Mar 02 | View |
| Mar 03, 2023 | David Ashley Lee | EXECUTIVE VP, COO & CFO | 3.178K | $13.41 | -$18.79K | GRANT | 0.87% | 369.777K | Mar 01 - Mar 02 | View |
| Mar 03, 2023 | Marshall Stanton | SVP, CLINICAL & MD AFFAIR | 2.756K | $13.41 | -$12.16K | GRANT | 5.59% | 52.077K | Mar 01 - Mar 02 | View |
| Mar 03, 2023 | John E Davis | SENIOR VP, GLOBAL SALES | 2.542K | $13.41 | -$15.03K | GRANT | 2.01% | 128.733K | Mar 01 - Mar 02 | View |
| Mar 03, 2023 | Jean F Holloway | SVP, GENERAL COUNSEL | 2.756K | $13.41 | -$12.16K | GRANT | 2.11% | 133.52K | Mar 01 - Mar 02 | View |
| Mar 01, 2023 | Amy Horton | VP, CHIEF ACCOUNTING OFFICER | 5.177K | $12.94 | -$18.36K | GRANT | 5.13% | 106.112K | Feb 23 - Feb 27 | View |
| Mar 01, 2023 | David Ashley Lee | EXECUTIVE VP, COO & CFO | 11.741K | $12.94 | -$40.03K | GRANT | 3.31% | 366.599K | Feb 23 - Feb 27 | View |
| Mar 01, 2023 | Jean F Holloway | SVP, GENERAL COUNSEL | 9.566K | $12.94 | -$25.36K | GRANT | 7.89% | 130.764K | Feb 23 - Feb 27 | View |
| Mar 01, 2023 | John E Davis | SENIOR VP, GLOBAL SALES | 9.007K | $12.94 | -$30.96K | GRANT | 7.69% | 126.191K | Feb 23 - Feb 27 | View |
| Mar 01, 2023 | Rochelle Maney | VP, QUALITY | 4.522K | $13.00 | -$26.95K | GRANT | 19.21% | 28.061K | Feb 23 - Feb 28 | View |
| Mar 01, 2023 | Andrew M Green | VP REGULATORY | 5.271K | $12.94 | -$22.60K | GRANT | 27.99% | 24.102K | Feb 23 - Feb 27 | View |
| Mar 01, 2023 | James P Mackin | PRESIDENT & CEO | 47.8K | $12.94 | -$292.79K | GRANT | 9.71% | 540.052K | Feb 23 - Feb 27 | View |
| Mar 01, 2023 | Dennis Maier | SVP, OPERATIONS | 7.758K | $12.94 | -$30.15K | GRANT | 19.07% | 48.436K | Feb 23 - Feb 27 | View |
| Mar 01, 2023 | Marshall Stanton | SVP, CLINICAL & MD AFFAIR | 8.873K | $12.94 | -$30.24K | GRANT | 21.94% | 49.321K | Feb 23 - Feb 27 | View |
| Mar 01, 2023 | Matthew A Getz | VP, HUMAN RESOURCES | 4.996K | $12.94 | -$20.70K | GRANT | 16.58% | 35.128K | Feb 23 - Feb 27 | View |
| Feb 21, 2023 | Amy Horton | VP, CHIEF ACCOUNTING OFFICER | 985 | $12.16 | -$65.57K | SELL-OPTIONS | 0.99% | 100.935K | Feb 17 - Feb 19 | View |
| Feb 16, 2023 | David Ashley Lee | EXECUTIVE VP, COO & CFO | 4.922K | $11.73 | -$44.82K | SELL-OPTIONS | 1.39% | 358.123K | Feb 14 | View |
| Feb 16, 2023 | James P Mackin | PRESIDENT & CEO | 9.049K | $11.73 | -$75.99K | SELL-OPTIONS | 1.82% | 505.684K | Feb 14 | View |
| Dec 16, 2022 | Amy Horton | VP, CHIEF ACCOUNTING OFFICER | -5.226K | $13.43 | -$70.20K | SELL | -4.97% | 99.95K | Dec 14 | View |
| Aug 18, 2022 | Rochelle Maney | VP, QUALITY | -7.161K | $22.96 | -$164.41K | SELL | -36.75% | 12.325K | Aug 16 | View |
| Aug 10, 2022 | Dennis Maier | SVP, OPERATIONS | -5.762K | $21.61 | -$124.51K | SELL | -20.17% | 22.807K | Aug 09 | View |
| Feb 11, 2022 | James P Mackin | PRESIDENT & CEO | 0 | $14.50 | -$148.94K | SELL-OPTIONS | 0.00% | 304.178K | Feb 09 - Feb 10 | View |
| Feb 10, 2022 | James P Mackin | PRESIDENT & CEO | 0 | $14.37 | -$71.75K | SELL-OPTIONS | 0.00% | 304.178K | Feb 08 | View |
| Feb 08, 2022 | James P Mackin | PRESIDENT & CEO | 0 | $14.15 | -$67.03K | SELL-OPTIONS | 0.00% | 304.178K | Feb 07 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.